Загрузка...
Key questions about the checkpoint blockade-are microRNAs an answer?
The introduction of immune-checkpoint blockade in the cancer therapy led to a paradigm change of the management of late stage cancers. There are already multiple FDA approved checkpoint inhibitors and many other agents are undergoing phase 2 and early phase 3 clinical trials. The therapeutic indicat...
Сохранить в:
| Опубликовано в: : | Cancer Biol Med |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Chinese Anti-Cancer Association
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5994554/ https://ncbi.nlm.nih.gov/pubmed/29951335 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.20892/j.issn.2095-3941.2018.0006 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|